Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome - A Monocentric, Prospective, Randomized, Double-blind and Placebo-controlled Phase 2 Trial
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Trichuris suis ova (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms TRIOMS
- 05 May 2016 Status changed from completed to discontinued.
- 31 Mar 2016 Status changed from recruiting to completed as per European Clinical Trials Database.
- 16 Sep 2013 Planned end date changed from 1 Dec 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.